Deutsche Märkte öffnen in 2 Stunden 43 Minuten

Eisai Co., Ltd. (ESALF)

Other OTC - Other OTC Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
61,50-2,03 (-3,20%)
Börsenschluss: 09:34AM EST

Eisai Co., Ltd.

4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp

Sektor(en)Healthcare
BrancheDrug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter11.322

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Haruo NaitoCEO, Representative Corp. Officer & Director785,65kN/A1947
Mr. Gary HendlerSr. VP & Pres of EMEA Region933,38kN/A1966
Dr. Lynn D. Kramer FAAN, M.D.VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health799,09kN/A1950
Ms. Yanhui FengSr. VP738,65kN/A1972
Dr. Nadeem Sarwar Ph.D.PresN/AN/AN/A
Mr. Tatsuyuki YasunoSr. VP, CFO & Chief IR OfficerN/AN/A1968
Mr. Kenta TakahashiExec. VP, Gen. Counsel & Intellectual Property Internal AuditN/AN/A1959
Mr. Yosuke AkitaVP, Chief Compliance Officer & Chief Information Security OfficerN/AN/A1965
Ms. Sayoko SasakiVP of Corp. Communications & ESGN/AN/A1968
Mr. Teruyuki MasakaVP & Chief HR OfficerN/AN/A1978
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Corporate Governance

Eisai Co., Ltd.s ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 6, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.